Enzyme vs Venom — how do they compare? Enzyme trades at Rp30,212 (market cap Rp134,13M, Rp104,56M 24h volume), while Venom trades at Rp333.71 (market cap Rp340,86M, Rp2,89M 24h volume). The key difference: Venom is far larger — about 2.5× Enzyme's market cap, and Venom's supply is capped (988,9M / 8B VENOM (13%)) while Enzyme's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold Enzyme for 29 Days and Venom for 24 Days on average.
| MLN | VENOM | |
|---|---|---|
Market Cap | Rp134,13M | Rp340,86M |
Volume (24h) | Rp104,56M | Rp2,89M |
Circulating Supply | 3,3M MLN | 988,9M / 8B VENOM (13%) |
Typical Hold Time | 29 Days | 24 Days |
Signals from Pluang's Aura AI — not financial advice
Enzyme (MLN) shows limited market activity with a modest market cap of Rp134,13M and circulating supply of 3,3jt tokens. The asset demonstrates relatively low volatility with an average hold time of 29 days, suggesting stable holder behavior. Trading volumes appear subdued across exchanges, indicating limited speculative interest. No significant protocol upgrades or ecosystem developments have been reported recently, though the project continues to operate its decentralized asset management platform.
Overall outlook remains cautious due to limited liquidity and trading activity. Key opportunities include potential ecosystem growth in decentralized finance asset management, while major risks include low market depth, regulatory uncertainty for DeFi protocols, and competition from larger DeFi platforms. The token's utility within its native protocol remains its primary value driver.
VENOM displays limited market activity with a modest market cap of Rp340.86M and only 13% of its maximum 8M token supply in circulation. The asset shows minimal trading volume and network activity, with an average hold time of 24 days indicating cautious investor behavior. No recent protocol updates or significant ecosystem developments have been observed, suggesting stagnant project growth.
Overall outlook remains cautious due to limited liquidity and adoption. Key opportunity lies in potential future protocol development, while major risks include extreme volatility from low market depth and regulatory uncertainty in the crypto space. Investors should monitor for any signs of renewed developer activity or exchange listings.
Enzyme is an easy-to-use on-chain asset management system that enables access to digital assets and DeFi from one simple, unified app. It provides a front-to-back execution and order management system, which provides fully automated reporting, risk management, administration, governance and operations.
Read more on MLN →Venom is a Layer 0 and Layer 1 network built on mesh technology that supports large-scale platforms like stablecoins and CBDCs. Its high scalability, speed, and low fees make it ideal for Web3 dApps, ensuring security and stability for high-load systems.
Read more on VENOM →